Stay updated with breaking news from Trial Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New phase 2b data from the FRONTIER 1 study showed promise for what could become the first and only oral IL-23 antagonist peptide for psoriasis.
This segment of her interview with HCPLive featured a discussion with Ferris on the FRONTIER 1 phase 2b trial results and their implications for psoriasis patients.
Get the Latest Info!
The expert panel discusses the secondary analysis from the phase 3 BRAVE clinical trials of baricitinib in alopecia areata.
It. >> carley: houm /* houm how many boosters should people get in a year? >> if you don't have natural immunity, maybe it makes sense, some doctors recommend it, philosophy of public health officials, the public is too stupid to understand the nuance of risk/benefit ratio by age group and risk is 10,000 fold different in older person versus a young healthy child. >> carley: researchers will stfda approval process for ecstasy after it cured -- >> this is interesting, we have early trial data from last year that showed 345 participantses in a study with this drug, mdna